Get the Stockscreener App
32.47
2.52%
-0.84
Pre-market:
32.99
0.52
+1.60%
Parabilis Medicines Inc stock is traded at $32.47, with a volume of 1.17M.
It is down -2.52% in the last 24 hours and down -15.51% over the past month.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
See More
Previous Close:
$33.31
Open:
$33.32
24h Volume:
1.17M
Relative Volume:
1.83
Market Cap:
$4.01B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-20.57%
1M Performance:
-15.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$31.06
$33.73
1-Week Range:
$31.06
$42.48
52-Week Range:
$24.51
$42.48
Parabilis Medicines Inc Stock (PBLS) Company Profile
Name
Parabilis Medicines Inc
Sector
Industry
Phone
-
Address
-
Compare PBLS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
32.47 | 4.01B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc Stock (PBLS) Latest News
Top Parabilis Medicines (PBLS) Competitors 2026 - MarketBeat
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 6.3%What's Next? - MarketBeat
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to S&P TMI Index - marketscreener.com
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biotech Stocks At 52-Week HighsMNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to Russell 3000 Value Benchmark - marketscreener.com
Parabilis Medicines (NASDAQ:PBLS) Hits New 52-Week HighTime to Buy? - MarketBeat
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $45 - Moomoo
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC - MarketBeat
PBLS: Zolucatetide advances as a multi-indication therapy, with strong data and broad pipeline expansion - TradingView
Parabilis at Morgan Stanley conference: broad bet on beta-catenin - Investing.com
PBLS: Zolucatetide's clinical progress and platform innovation drive a broad pipeline and major upcoming milestones - TradingView
Parabilis Medicines (NASDAQ:PBLS) Trading Up 6%Still a Buy? - MarketBeat
Parabilis Medicines to Showcase Updated Zolucatetide Trial Results at ESMO 2026 - Kalkine Media
WINTON GROUP Ltd Takes Position in Parabilis Medicines, Inc. $PBLS - marketbeat.com
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Parabilis Medicines (PBLS) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewswire
ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat
1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat
venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView
Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Yahoo Finance
ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Parabilis Medicines Inc Stock (PBLS) Financials Data
There is no financial data for Parabilis Medicines Inc (PBLS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Parabilis Medicines Inc Stock (PBLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '26 |
Buy |
29.25 |
65,923 |
1,928,032 |
26,482,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 22 '26 |
Buy |
29.77 |
47,250 |
1,406,632 |
26,529,686 |
| Levy Guy | 10% Owner |
Jun 11 '26 |
Buy |
20.00 |
500,000 |
10,000,000 |
1,027,000 |
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):